Special Issue

Neuromuscular Disorders in Children and Adolescents

Message from the Guest Editor

During the last decades, significant scientific and therapeutic progress has been achieved in neuromuscular disorders (NMD) of childhood. In 1985, Duchenne Muscular Dystrophy (DMD) was the first genetic disease whose genetic code could be deciphered. Since that time, continuously new genetic entities of NMDs were defined. Consequently, the classification of these diseases changed from a clinicaldescriptive and formal-genetic to a molecular-genetic and pathophysiological one. This resulted in intensified research in the biology and therapy of these diseases, in the last years resulting in first effective gene-modifying treatments in DMD and Spinal Muscular Atrophy (SMA), and recently, gene replacement therapy in the most severe form of SMA. Despite this significant progress in therapeutic research, the way to cure or significantly improve life for most children and adolescents with neuromuscular disorders is still unknown and a long way off. Nevertheless, great progress has also been made in symptomatic and rehabilitative management, allowing one to significantly improve functioning and quality of life of the affected individuals and their families.

Guest Editor

Prof. Rudolf Korinthenberg

Research Ethics Comittee, University of Freiburg, 79106 Freiburg, Germany

Deadline for manuscript submissions

closed (10 December 2021)



Children

an Open Access Journal by MDPI

Impact Factor 2.1
CiteScore 3.8
Indexed in PubMed



mdpi.com/si/74715

Children
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
children@mdpi.com

mdpi.com/journal/children





Children

an Open Access Journal by MDPI

Impact Factor 2.1 CiteScore 3.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or comprehensive review for consideration and publication in *Children* (ISSN 2227-9067). *Children* is an open access journal—research articles, reviews, and other content are published online immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. The journal focuses on sharing clinical, epidemiological, and translational science relevant to children's health. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Paul R. Carney

Departments of Child Health and Neurology, University of Missouri, 400 Keene Street, Columbia, MO 65211, USA

Author Benefits

Open Access

 free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q2 (Pediatrics) / CiteScore - Q2 (Pediatrics, Perinatology and Child Health)

